Assessment of Hypersensitivity Reactions and Feasibility of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-Cell Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) at a Comprehensive Cancer Center

Trial Profile

Assessment of Hypersensitivity Reactions and Feasibility of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-Cell Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) at a Comprehensive Cancer Center

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Feb 2015

At a glance

  • Drugs Rituximab (Primary)
  • Indications B cell lymphoma; Chronic lymphocytic leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 28 Aug 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 28 Aug 2013 Planned End Date changed from 1 Feb 2013 to 1 May 2014 as reported by ClinicalTrials.gov.
    • 05 Nov 2012 Planned End Date changed from 1 Feb 2012 to 1 Feb 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top